New hope for HIV patients: cheaper chemo may work just as well for kaposi sarcoma
NCT ID NCT05411237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two different chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, work equally well for treating Kaposi sarcoma in people living with HIV in sub-Saharan Africa. About 130 participants will receive one of the drugs every three weeks for six cycles. The main goal is to see how long the cancer stays under control and to compare side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIDS-RELATED KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo